Publications

Despite major progress in the treatment of RA over the past decade, sustained clinical remission remains elusive. The identification of new treatment targets is therefore necessary, with much research currently being undertaken in this area. Novel therapeutic approaches currently being investigated include T cell-directed therapies targeting both T cell activation and regulation; and the targeting of pathogenic B cell functions, including the use of depleting and non-depleting B cell-directed antibodies. Compounds targeting GM-CSF, IL-17, IL-20, and IL-21 are also in clinical development. Burmester et al. review these and other novel approaches in the context of RA treatment in the future.